Teduglutide (Gattex / Revestive): GLP-2 Analog for Short Bowel Syndrome — Research Overview

Teduglutide (brand names Gattex in the United States, Revestive in Europe) is a recombinant GLP-2 analog that represents a milestone in the management of short bowel syndrome with intestinal failure (SBS-IF). Approved by the FDA in December 2012, it was the first intestinotrophic therapy approved for adults with SBS-IF and was subsequently approved for pediatric patients. For patients who have lost large segments of small intestine through surgical resection, teduglutide offers the prospect of reducing — and in some cases eliminating — dependence on long-term parenteral nutrition (PN) or intravenous fluids.

What Is Teduglutide?

Teduglutide is a 33-amino acid peptide analog of native GLP-2, a hormone produced by intestinal L-cells in response to nutrient ingestion. It differs from endogenous GLP-2 by a single amino acid substitution at position 2 (alanine replaced by glycine), which renders it resistant to cleavage by dipeptidyl peptidase-IV (DPP-IV). This modification substantially extends its biological half-life compared with the native hormone, making it suitable for once-daily subcutaneous dosing.

Short bowel syndrome arises most commonly from massive surgical resection of the small intestine due to Crohn's disease, mesenteric ischemia, volvulus, or trauma. The resulting intestinal failure leads to chronic malabsorption, and many patients require long-term parenteral nutrition to sustain life. Teduglutide targets the GLP-2 receptor in the intestinal mucosa to promote adaptive regrowth and restore absorptive capacity.

Mechanism of Action

Teduglutide binds to the GLP-2 receptor (GLP2R), a G-protein-coupled receptor expressed on intestinal epithelial cells, enteric neurons, and subepithelial myofibroblasts. Activation of GLP2R triggers intracellular cAMP signaling cascades that stimulate intestinal mucosal growth (villus hypertrophy and crypt hyperplasia), increase intestinal blood flow, reduce intestinal permeability, and inhibit gastric acid secretion and motility.

These combined effects increase the absorptive surface area of the remaining intestine and slow transit time, allowing greater uptake of fluid and nutrients. In patients with SBS-IF, this translated to clinically meaningful reductions in required PN volume in pivotal clinical trials. Because GLP2R is also expressed on tissues outside the gastrointestinal tract — including pancreatic and biliary duct cells — the FDA label requires surveillance colonoscopy before initiation and periodically during treatment to monitor for intestinal polyp growth.

What the Research Shows

The pivotal evidence base for teduglutide rests on the STEPS program, a series of Phase III randomized controlled trials. The landmark STEPS-1 trial, published by Jeppesen et al. in 2012, enrolled 86 adults with SBS-IF and randomized them to subcutaneous teduglutide 0.05 mg/kg/day or placebo for 24 weeks. The primary endpoint — at least a 20% reduction in weekly PN volume — was met by 63% of teduglutide-treated patients compared with 30% of placebo recipients (P = 0.002). Mean weekly PN volume decreased by 4.4 L in the teduglutide group versus 2.3 L in the placebo group (P < 0.001).

A second 24-week Phase III trial (STEPS-2, Jeppesen 2012, PMID 22982184) confirmed that a greater proportion of teduglutide-treated patients were able to reduce PN infusion days. A long-term open-label extension study demonstrated sustained benefits over 30 months, with some patients achieving complete weaning from parenteral support.

A pooled safety analysis across four clinical trials (Pape et al. 2020) in 159 adults with SBS-IF confirmed that the most common adverse events were abdominal pain, nausea, injection-site reactions, and headache. Stoma output increase was also reported. Rates of serious adverse events were comparable between active and placebo arms in the controlled period. The FDA label requires colonoscopy surveillance because of the intestinotrophic mechanism and potential for polyp acceleration.

Pharmacokinetics

Teduglutide is administered as a once-daily subcutaneous injection. Following subcutaneous dosing, absolute bioavailability is approximately 88%. Peak plasma concentrations (Tmax) are reached at roughly 3–5 hours. The half-life of teduglutide is approximately 2 hours in healthy subjects and slightly longer in patients with SBS due to reduced renal function. The peptide is primarily degraded by ubiquitous proteases; renal clearance plays a role and dose adjustment is recommended in patients with moderate or severe renal impairment (CrCl < 50 mL/min), where the FDA label specifies halving the dose.

Teduglutide does not appear to inhibit or induce cytochrome P450 enzymes at therapeutic concentrations. Drug–drug interaction potential through metabolic pathways is considered low, though increased intestinal absorption of concomitant oral medications has been observed clinically and warrants monitoring.

Approved Indications and Clinical Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Teduglutide (Gattex) is FDA-approved for the treatment of adults and pediatric patients one year of age and older with short bowel syndrome who are dependent on parenteral support. The FDA label specifies a dose of 0.05 mg/kg administered subcutaneously once daily. For patients with moderate or severe renal impairment (CrCl < 50 mL/min), the label specifies reducing the dose to 0.025 mg/kg/day. The label does not support use in patients with active gastrointestinal malignancy.

The clinical trials used weight-based dosing exclusively. Individualized dosing, titration schedules, and duration of therapy are determined by the treating clinical team in the context of ongoing assessment of PN requirements. The label requires colonoscopy or other imaging within six months before starting treatment and at least every five years thereafter.

Storage and Handling

Teduglutide (Gattex) is supplied as a lyophilized powder in single-dose vials. The FDA label specifies storage of unopened vials at room temperature up to 25°C (77°F); refrigeration at 2–8°C (36–46°F) is also acceptable. After reconstitution with the provided diluent, the reconstituted solution should be used immediately or within three hours if stored at room temperature. The reconstituted solution should not be frozen. Each vial is for single use only; any unused portion must be discarded.

What Teduglutide Is NOT

Teduglutide is sometimes confused with semaglutide or liraglutide because all three are peptide analogs of glucagon-family hormones. The key distinction is receptor target and therapeutic niche: semaglutide and liraglutide are GLP-1 receptor agonists used for type 2 diabetes and obesity, while teduglutide is a GLP-2 receptor agonist whose action is localized to intestinal mucosal growth. Teduglutide has no meaningful effect on insulin secretion, blood glucose, or body weight in patients without SBS. It is not a metabolic or weight-loss agent.

Teduglutide is also distinct from native GLP-2 (which has a very short half-life and is not a pharmaceutical product) and from glucagon itself (GLP-2 is a post-translational cleavage product of preproglucagon, not the parent hormone). It should not be confused with HGF (hepatocyte growth factor), EGF (epidermal growth factor), or other intestinotrophic factors that have been studied experimentally.

References

1. Jeppesen PB, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473–1481. PMID 22982184.

2. Jeppesen PB, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60(7):902–914. PMID 21317170.

3. Pape UF, et al. Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials. Therapeutic Advances in Gastroenterology. 2020;13:1756284820905766.

4. U.S. FDA. Gattex (teduglutide) Prescribing Information. NDA 203441. Updated 2024. Available at accessdata.fda.gov.